This virtual event is free on Zoom. It begins at 5:00 pm.
JDRF is excited to share with you an update on using stem cell replacement therapy as a functional cure for T1D! ViaCyte, a JDRF-supported regenerative medicine company, has demonstrated that its stem cell-derived islet replacement cells, when effectively engrafted, are capable of producing insulin in T1D patients. We invite you to join Dr. Manasi Sinha Jaiman, VP of Clinical Development, and Mark Daniels, Director of Clinical Development, for an update on ViaCyte’s product candidates and the current progress in their human clinical trials. Advancing research in beta cell replacement is a core pillar of JDRF’s research strategy. We think you will find this fascinating and hope you will join us!